Indirect comparisons of efficacy and weekly factor consumption during continuous prophylaxis with recombinant factor VIII Fc fusion protein and conventional recombinant factor VIII products

Recombinant factor VIII (rFVIII) products with extended half‐lives have the potential to improve adherence and outcomes in haemophilia beyond the results obtained with conventional rFVIII products.

[1]  S. Krichevsky,et al.  50th ASH Annual Meeting and Exposition , 2016 .

[2]  V. Jiménez‐Yuste,et al.  Prospective surveillance study of haemophilia A patients switching from moroctocog alfa or other factor VIII products to moroctocog alfa albumin-free cell culture (AF-CC) in usual care settings , 2015, Thrombosis and Haemostasis.

[3]  R. Furlan,et al.  Adherence to prophylaxis is associated with better outcomes in moderate and severe haemophilia: results of a patient survey , 2015, Haemophilia : the official journal of the World Federation of Hemophilia.

[4]  M. Witkop,et al.  Better adherence to prescribed treatment regimen is related to less chronic pain among adolescents and young adults with moderate or severe haemophilia , 2014, Haemophilia : the official journal of the World Federation of Hemophilia.

[5]  J. Dumont,et al.  Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. , 2014, Blood.

[6]  S. Jackson,et al.  An objective method for assessing adherence to prophylaxis in adults with severe haemophilia , 2014, Haemophilia : the official journal of the World Federation of Hemophilia.

[7]  J. Oldenburg,et al.  Consumption Of FVIII Concentrate During On-Demand and Prophylactic Treatment With Human-cl rhFVIII In Prospective Clinical Studies In Adult Patients With Severe Hemophilia A , 2013 .

[8]  M. Ozelo,et al.  Results from a large multinational clinical trial (guardian™1) using prophylactic treatment with turoctocog alfa in adolescent and adult patients with severe haemophilia A: safety and efficacy , 2013, Haemophilia : the official journal of the World Federation of Hemophilia.

[9]  K. Fischer,et al.  Barriers and motivators of adherence to prophylactic treatment in haemophilia: a systematic review , 2013, Haemophilia : the official journal of the World Federation of Hemophilia.

[10]  J. Epstein,et al.  Treatment patterns, health‐related quality of life and adherence to prophylaxis among haemophilia A patients in the United States , 2012, Haemophilia : the official journal of the World Federation of Hemophilia.

[11]  L. Valentino,et al.  A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management , 2012, Journal of thrombosis and haemostasis : JTH.

[12]  L. Mantovani,et al.  A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study) , 2011, Journal of thrombosis and haemostasis : JTH.

[13]  C. Porta,et al.  Indirect treatment comparison of bevacizumab + interferon-α-2a vs tyrosine kinase inhibitors in first-line metastatic renal cell carcinoma therapy , 2011, ClinicoEconomics and outcomes research : CEOR.

[14]  Max E Valentinuzzi,et al.  SAFETY AND EFFICACY , 2010 .

[15]  W. Kronenberger,et al.  VERITAS‐Pro: a new measure of adherence to prophylactic regimens in haemophilia , 2010, Haemophilia : the official journal of the World Federation of Hemophilia.

[16]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement , 2009, BMJ.

[17]  P. Mannucci,et al.  Clinical evaluation of moroctocog alfa (AF‐CC), a new generation of B‐domain deleted recombinant factor VIII (BDDrFVIII) for treatment of haemophilia A: demonstration of safety, efficacy, and pharmacokinetic equivalence to full‐length recombinant factor VIII , 2009, Haemophilia : the official journal of the World Federation of Hemophilia.

[18]  J. Astermark,et al.  Break‐through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A , 2009, Journal of thrombosis and haemostasis : JTH.

[19]  J. Stockman.  Prophylaxis versus Episodic Treatment to Prevent Joint Disease in Boys with Severe Hemophilia , 2009 .

[20]  H. M. van den Berg,et al.  A survey of adherence to haemophilia therapy in six European countries: results and recommendations , 2008, Haemophilia : the official journal of the World Federation of Hemophilia.

[21]  A. Shapiro.  Anti-hemophilic factor (recombinant), plasma/albumin-free method (octocog-alpha; ADVATE®) in the management of hemophilia A , 2007, Vascular health and risk management.

[22]  J. Rice,et al.  Quantifying adherence to treatment and its relationship to quality of life in a well‐characterized haemophilia population , 2007, Haemophilia : the official journal of the World Federation of Hemophilia.

[23]  A. Ganser,et al.  Efficacy, safety and tolerability of recombinant factor VIII (REFACTO®) in patients with haemophilia A: interim data from a postmarketing surveillance study in Germany and Austria , 2007, Haemophilia : the official journal of the World Federation of Hemophilia.

[24]  J. Maahs,et al.  Practice patterns in haemophilia A therapy – global progress towards optimal care , 2006, Haemophilia : the official journal of the World Federation of Hemophilia.

[25]  A. Iorio,et al.  Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B. , 2006, The Cochrane database of systematic reviews.

[26]  A. Shapiro,et al.  Clinical evaluation of an advanced category antihaemophilic factor prepared using a plasma/albumin‐free method: pharmacokinetics, efficacy, and safety in previously treated patients with haemophilia A 1 , 2004, Haemophilia : the official journal of the World Federation of Hemophilia.

[27]  D. Altman,et al.  Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.

[28]  S. Thompson,et al.  Quantifying heterogeneity in a meta‐analysis , 2002, Statistics in medicine.

[29]  M. Manco‐Johnson,et al.  Barriers to compliance with prophylaxis therapy in haemophilia , 2001, Haemophilia : the official journal of the World Federation of Hemophilia.

[30]  N. Laird,et al.  Meta-analysis in clinical trials. , 1986, Controlled clinical trials.